Israel – a country that receives almost half of its research and development investments from foreign capital – is a striking example of how international financing can contribute to the strength of an innovation ecosystem, according to a posting on the website of Swiss pharma trade group Interpharma.
Switzerland, on the other hand, only receives 6% of its R&D investments from foreign sources. Interpharma said a comparison that raises questions is: Could more international capital also strengthen Switzerland as an innovation location?
Israel's success model: A focus on global markets
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze